orphenadrine has been researched along with Basal Ganglia Diseases in 8 studies
Orphenadrine: A muscarinic antagonist used to treat drug-induced parkinsonism and to relieve pain from muscle spasm.
orphenadrine : A tertiary amino compound which is the phenyl-o-tolylmethyl ether of 2-(dimethylamino)ethanol.
Basal Ganglia Diseases: Diseases of the BASAL GANGLIA including the PUTAMEN; GLOBUS PALLIDUS; claustrum; AMYGDALA; and CAUDATE NUCLEUS. DYSKINESIAS (most notably involuntary movements and alterations of the rate of movement) represent the primary clinical manifestations of these disorders. Common etiologies include CEREBROVASCULAR DISORDERS; NEURODEGENERATIVE DISEASES; and CRANIOCEREBRAL TRAUMA.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 8 (100.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Tyrer, P | 1 |
| Alexander, MS | 1 |
| Regan, A | 1 |
| Lee, I | 1 |
| Mindham, RH | 2 |
| Rossi, B | 1 |
| Vignocchi, G | 1 |
| Siciliano, G | 1 |
| Risaliti, R | 1 |
| Soni, SD | 1 |
| Johnson, DA | 1 |
| Altamura, AC | 1 |
| Buccio, M | 1 |
| Colacurcio, F | 1 |
| Colombo, G | 1 |
| Terzi, A | 1 |
| Gaind, R | 1 |
| Anstee, BH | 1 |
| Rimmer, L | 1 |
| Müller, D | 1 |
| Neumärker, KJ | 1 |
| Böhl, I | 1 |
| Schulz, H | 1 |
| Morselli, PL | 1 |
| Rizzo, M | 1 |
| Zaccala, M | 1 |
| Garattini, S | 1 |
2 trials available for orphenadrine and Basal Ganglia Diseases
| Article | Year |
|---|---|
Assessment of drugs in schizophrenia. Asessment of drug-induced extrapyramidal reactions and of drugs given for their control.
Topics: Amantadine; Antiparkinson Agents; Antipsychotic Agents; Basal Ganglia Diseases; Clinical Trials as T | 1976 |
Comparison of amantadine, orphenadrine, and placebo in the control of phenothiazine-induced Parkinsonism.
Topics: Affect; Amantadine; Basal Ganglia Diseases; Clinical Trials as Topic; Evaluation Studies as Topic; F | 1972 |
6 other studies available for orphenadrine and Basal Ganglia Diseases
| Article | Year |
|---|---|
An extrapyramidal syndrome after lithium therapy.
Topics: Aged; Basal Ganglia Diseases; Drug Synergism; Female; Humans; Lithium; Middle Aged; Orphenadrine; Tr | 1980 |
Effects of anticholinergic agents on the excitability of the blink reflex in Meige syndrome.
Topics: Aged; Basal Ganglia Diseases; Blinking; Female; Humans; Meige Syndrome; Middle Aged; Orphenadrine; P | 1989 |
Anticholinergic anti-Parkinson medication for neuroleptic-induced extrapyramidal side effects.
Topics: Antipsychotic Agents; Basal Ganglia Diseases; Humans; Orphenadrine | 1986 |
Orphenadrine plasma levels and amelioration of extrapyramidal side effects in schizophrenic patients treated with haloperidol.
Topics: Adolescent; Adult; Basal Ganglia Diseases; Female; Haloperidol; Humans; Male; Middle Aged; Orphenadr | 1986 |
[Influence of intravenously administered orphenadrine citrate (Norflex) on the EEG in children].
Topics: Adolescent; Basal Ganglia Diseases; Cerebral Cortex; Child; Child, Preschool; Electroencephalography | 1973 |
Haloperidol-desipramine interaction in mice, rats and man.
Topics: Animals; Basal Ganglia Diseases; Benperidol; Butyrophenones; Chronic Disease; Desipramine; Drug Anta | 1970 |